

LIST OF APPENDICES

	Appendix to Issue	Page
Information supplied by the Department of Defence Production with reference to last purchase of drugs by that department.....	A	23 1550-55
Standard for Manufacture, Control and Distribution of Drugs, 74-GP-lb-7 October 1966, DDP.....	B	23 1556-64
Brief of the Canadian Wholesale Drug Association.....	A	24 1604-32
1965 CWDA Operating Survey.....	B	24 1633-46
CWDA Service Survey.....	C	24 1647-58
Submission of the Canadian Cystic Fibrosis Foundation ..	A	25 1676-91
Letter from the Treasurer and Controller of Cyanamid of Canada Limited, Nov. 15, 1966, re: definition of Investment.....	A	26 1738-39
Letter from the President of Charles E. Frosst & Co., Nov. 15, 1966, re: sale of Frosst products in export markets.	B	26 1740-41
Letter from the Executive Director of the Ontario Pharmacists' Association, Nov. 16, 1966.....	C	26 1742
Brief of Jules R. Gilbert, Ltd.....	D	26 1743-60
Submission of Micro Chemicals Limited, Gryphon Laboratories Limited and Paul Maney Laboratories Canada Limited.....	A	27 1810-37
Letter of the Vice-President and General Manager of Smith Kline & French Inter-American Corporation to the Chairman of the Committee.....	B	27 1838-44
Brief and memorandum of Prescription Services Inc.....	A	28 1873-84
Supplementary Brief of Canadian Pharmaceutical Association, Inc.....	A	29 1931-80
Submission from The Canadian Drug Manufacturers on the subject matter of Sales Tax on Pharmaceuticals ..	A	30 2089-99
Summary of Data on Drugs, FDD.....	B	30 2100-07
Some Observations on Drug Control in Europe.....	C	30 2108-13
Examination of Trifluoperazine Tablets Marketed in Canada.....	D	30 2114-35
Correspondence relating to the question of the "new drug" status of Trifluoperazine, and to the recommendations of the Hilliard Committee in this regard.....	E	30 2136-46
Letter to the Legal Counsel for the Committee from the Executive Vice-President of PMAC.....	F	30 2147-48
Letter from the Solicitor for Hoffmann-La Roche re: Submission of Micro Chemicals Limited, Gryphon Laboratories Limited and Paul Maney Laboratories Canada Limited.....	G	30 2149-51
Letter from the Assistant Secretary of Hoffmann-La Roche Limited to the Chairman of the Committee.....	H	30 2152-53
Report entitled "The Cost of Pharmaceuticals and Medicines in Canada, 1961-1965".....	A	32 2257-82
Letter from the Hon. Minister of National Health and Welfare to the Chairman of the Committee (Jan. 27, 1967).....	B	32 2283
Letter from the Accountant of the Committee enclosing six tables of statistics for the Pharmaceutical Manufacturing Industry in Canada.....	A	33 2401-04
Letter from the Chairman of Canadian Drug Manufacturers, and additional description on the sales tax on pharmaceuticals.....	B	33 2405-06
Letter from the Registrar of the Pharmaceutical Association of the Province of British Columbia, with reference to brief presented by Mr. S. S. Bass, of London Drugs..	C	33 2407-10
Letter from the Vice-President and Managing Director of Parke, Davis & Company, Ltd. supplying additional information.....	D	33 2411